RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 ADVANCE Results: PEG-IFN-β-1a Decreases Disability in RRMS
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 29
SP 7
OP 7
DO 10.1177/155989771429003
UL http://mdc.sagepub.com/content/14/29/7.abstract
AB Two-year data from the Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis [ADVANCE; NCT00906399; Kieseier BC et al. ECTRIMS 2014 (poster P042)], a study of relapsing-remitting multiple sclerosis (RRMS) in more than 1500 patients, have confirmed the long-term capability of subcutaneously injected peginterferon beta-1a (PEG-IFN-β-1a) in lessening disability progression.